Copyright
©The Author(s) 2022.
World J Clin Oncol. Jan 24, 2022; 13(1): 49-61
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
Published online Jan 24, 2022. doi: 10.5306/wjco.v13.i1.49
CID present | CID non present | |||||
CRC | LS specific1 | All other | CRC | LS specific | All other | |
MLH1 | 2 (40.0) | 2 (40.0) | 1 (20.0) | 2 (20.0) | 2 (20.0) | 0 (0) |
MSH2 | 2 (66.7) | 0 (0) | 1 (33.3) | 2 (28.6) | 4 (57.1) | 1 (14.3) |
MSH6 | 0 (0) | 0 (0) | 0 (0) | 2 (50.0) | 1 (25.0) | 0 (0) |
PMS2 | 2 (50.0) | 0 (0) | 1 (25.0) | 0 (0) | 2 (25.0) | 0 (0) |
No MMRPV | 3 (42.9) | 1 (14.3) | 1 (14.3) | 6 (42.9) | 1 (7.1) | 0 (0) |
- Citation: Faisal MS, Burke CA, Liska D, Lightner AL, Leach B, O’Malley M, LaGuardia L, Click B, Achkar J, Kalady M, Church J, Mankaney G. Association of cancer with comorbid inflammatory conditions and treatment in patients with Lynch syndrome. World J Clin Oncol 2022; 13(1): 49-61
- URL: https://www.wjgnet.com/2218-4333/full/v13/i1/49.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i1.49